^
    Back
    Association details:
    Biomarker:ESR1 mutation
    Cancer:Breast Cancer
    Drug:Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    JCO Precis Oncol
    Title:

    A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression

    Published date:
    05/04/2023
    Excerpt:
    We investigated a gene panel to prognosticate abemaciclib susceptibility in patients with ESR1-MUT MBC after palbociclib progression….For ESR1-MUT MBC with resistance to ET and palbociclib, PFS on abemaciclib is longer for patients with CDKi-R(–) than CDKi-R(+).
    DOI:
    10.1200/PO.22.00532
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Gan To Kagaku Ryoho
    Title:

    [ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib]

    Published date:
    08/23/2023
    Excerpt:
    Here, we describe our experience of a case in which long-term PR was achieved with AI(letrozole)plus abemaciclib despite ESR1 mutation positivity in cancer genetic screening and review the literature.
    Secondary therapy:
    letrozole